MADRIGAL PHARMACEUTICALS, INC. (MDGL) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $2.77B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $808.00K.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $2.73B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.08M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $2.69B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $873.00K.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $2.00K; Additional Paid in Capital, Common StockUSD $2.66B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $1.07M.
MADRIGAL PHARMACEUTICALS, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature USD |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $2.00K | $2.77B | $808.00K | $-2.24B | $523.72M | 3 month · $35.37M | (m) | (m) | (m) | (m) |
| 2026-03-31 | $0.00 | $2.00K | $2.73B | $1.08M | $-2.18B | $543.45M | 3 month · $32.62M | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $2.00K | $2.69B | $873.00K | $-2.09B | $602.69M | 12 month · $98.13M | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $2.00K | $2.66B | $1.07M | $-2.03B | $625.73M | 3 month · $26.25M | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $2.00K | $2.61B | $1.11M | $-1.92B | $695.98M | 3 month · $25.16M | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $2.00K | $2.59B | $389.00K | $-1.88B | $710.64M | 3 month · $20.93M | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $2.00K | $2.56B | $468.00K | $-1.80B | $754.38M | 12 month · $79.88M | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $2.00K | $2.52B | $1.27M | $-1.74B | $777.15M | 3 month · $17.90M | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $2.00K | $2.49B | $-368.00K | $-1.64B | $857.12M | 3 month · $24.40M | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $2.00K | $2.33B | $-172.00K | $-1.48B | $850.76M | 3 month · $19.90M | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $2.00K | $1.74B | $468.00K | $-1.34B | $405.33M | 12 month · $49.73M | 12 month · $860.00K | (m) | (m) | (m) |
| 2023-09-30 | (m) | $2.00K | $1.25B | $-42.00K | $-1.22B | $22.25M | 3 month · $12.66M | 3 month · $121.00K | (m) | (m) | (m) |
| 2023-06-30 | (m) | $2.00K | $1.23B | $-89.00K | $-1.13B | $103.51M | 3 month · $10.97M | 3 month · $195.00K | (m) | (m) | (m) |
| 2023-03-31 | (m) | $2.00K | $1.19B | $-86.00K | $-1.04B | $150.14M | 3 month · $11.25M | 3 month · $544.00K | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $2.00K | $1.16B | $-32.00K | $-962.66M | $197.39M | 12 month · $31.62M | 12 month · $622.00K | (m) | (m) | (m) |
| 2022-09-30 | (m) | $2.00K | $887.66M | $-237.00K | $-876.75M | $10.67M | 3 month · $8.12M | (m) | (m) | (m) | (m) |
| 2022-06-30 | (m) | $2.00K | $879.54M | $-447.00K | $-795.56M | $83.53M | 3 month · $7.94M | 3 month · $622.00K | (m) | (m) | (m) |
| 2022-03-31 | (m) | $2.00K | $870.97M | $-402.00K | $-724.83M | $145.74M | 3 month · $7.48M | (m) | (m) | (m) | (m) |
| 2021-12-31 | (m) | $2.00K | $863.50M | $-80.00K | $-667.31M | $196.11M | 12 month · $26.87M | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $2.00K | $837.64M | $4.00K | $-602.76M | $234.88M | 3 month · $6.24M | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $2.00K | $810.29M | $15.00K | $-539.66M | $270.65M | 3 month · $8.18M | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $2.00K | $738.58M | $-14.00K | $-478.01M | $260.55M | 3 month · $6.10M | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $2.00K | $665.38M | $47.00K | $-425.46M | $239.97M | 12 month · $20.73M | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $2.00K | $655.62M | $421.00K | $-366.34M | $289.70M | 3 month · $5.06M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $2.00K | $650.21M | $1.08M | $-308.38M | $342.92M | 3 month · $5.69M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $2.00K | $644.41M | $415.00K | $-259.36M | $385.48M | 3 month · $4.85M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $2.00K | $639.57M | $216.00K | $-223.22M | $416.56M | 12 month · $22.76M | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $2.00K | $635.53M | $292.00K | $-195.48M | $440.35M | 3 month · $4.95M | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $2.00K | $630.55M | $485.00K | $-174.05M | $456.99M | 3 month · $7.75M | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $2.00K | $622.68M | $178.00K | $-154.35M | $468.51M | 3 month · $6.02M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | $2.00K | $616.57M | $-319.00K | $-139.27M | $476.98M | 12 month · $13.49M | (m) | (m) | (m) | (m) |
| 2018-09-30 | (m) | $2.00K | $610.85M | $-143.00K | $-127.80M | $482.91M | 3 month · $4.98M | (m) | (m) | (m) | (m) |
| 2018-06-30 | (m) | $2.00K | $605.42M | $-43.00K | $-119.28M | $486.09M | 3 month · $2.23M | (m) | (m) | (m) | (m) |
| 2018-03-31 | (m) | $1.00K | $290.18M | $-174.00K | $-112.83M | $177.18M | 3 month · $1.17M | (m) | (m) | (m) | (m) |
| 2017-12-31 | (m) | $1.00K | $288.75M | $-31.00K | $-106.46M | $182.26M | 12 month · $3.25M | (m) | (m) | (m) | (m) |
| 2017-09-30 | (m) | $1.00K | $152.28M | $47.00K | $-98.02M | $54.31M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $1.00K | $151.25M | $36.00K | $-89.65M | $61.63M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $1.00K | $115.69M | $64.00K | $-81.31M | $34.45M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $1.00K | $111.69M | $25.00K | $-75.31M | $36.41M | 12 month · $7.93M | (m) | (m) | 12 month · $7.93M | 12 month · $47.59M |
| 2016-09-30 | (m) | $1.16K | $105.16M | $-12.48K | $-67.56M | $37.59M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $14.00K | $757.63M | $81.00K | $-716.15M | $41.57M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $14.00K | $757.08M | $4.00K | $-712.77M | $44.33M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $18.00 | $6.21K | $4.00K | $-48.92M | $-48.91M | 12 month · $4.30M | (m) | (m) | (m) | (m) |
| 2015-09-30 | (m) | $14.00K | $756.05M | $11.00K | $-695.71M | $60.37M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | (m) | $13.00K | $747.05M | $-6.00K | $-678.08M | $68.98M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | (m) | $11.00K | $704.40M | $6.00K | $-658.28M | $46.14M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $11.00K | $702.69M | $4.00K | $-637.57M | $-42.07M | 12 month · $7.43M | (m) | (m) | (m) | (m) |
| 2014-09-30 | (m) | $11.00K | $700.93M | $11.00K | $-617.22M | $83.73M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | (m) | $10.00K | $671.24M | $3.00K | $-597.25M | $74.00M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $9.00K | $613.18M | $4.00K | $-574.97M | $38.22M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | $9.00K | $600.48M | $17.00K | $-551.41M | $49.09M | 12 month · $6.03M | (m) | (m) | (m) | (m) |
| 2013-09-30 | (m) | $7.00K | $541.85M | $6.00K | $-527.25M | $14.61M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | (m) | $7.00K | $540.15M | $9.00K | $-504.74M | $35.44M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | (m) | $7.00K | $538.54M | $7.00K | $-481.95M | $56.60M | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | (m) | $7.00K | $536.28M | $2.00K | $-461.22M | $75.07M | 12 month · $3.32M | (m) | (m) | (m) | (m) |
| 2012-09-30 | (m) | $6.00K | $475.27M | $8.00K | $-443.10M | $32.19M | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | (m) | $6.00K | $448.56M | $4.00K | $-428.10M | $20.46M | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | (m) | $6.00K | $447.23M | $19.00K | $-413.48M | $33.77M | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | (m) | $5.00K | $413.20M | $3.00K | $-398.43M | $14.77M | 12 month · $3.35M | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | $5.00K | $412.26M | $1.00K | $-387.69M | $24.58M | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | $5.00K | $411.38M | $10.00K | $-374.95M | (m) | (m) | (m) | $36.44M | (m) | (m) |
| 2010-12-31 | (m) | $4.00K | $374.53M | $-3.00K | $-351.05M | $23.48M | 12 month · $4.05M | (m) | $23.48M | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) | (m) | (m) | $24.91M | 12 month · $4.58M | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | (m) | (m) | (m) | (m) | $-58.79M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |